肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

BMJ：罕见滤泡性淋巴瘤侵犯皮肤病例报道

2015-11-07 seven L 译 MedSci原创

滤泡性淋巴瘤皮肤红斑
关注

71岁老年女性，面部有严重的丘疹-结节性红斑病变，且持续存在。查体：双侧颈部、腋窝和腹股沟淋巴结肿大。影像学：弥散性淋巴结肿大和肝脾肿大。皮肤和淋巴结活检： 低分化滤泡性淋巴瘤浸润皮肤。这种罕见的疾病通常会被误诊为肉芽肿性酒渣鼻、面部播散性粟疹样狼疮、持续性节肢动物叮咬反应、或其他炎症性皮肤病。该疾病通常可以通过组织活检得出精确诊断。原发的皮肤滤泡性淋巴瘤更常见，不过如果患者出现了全身症状，则该诊

71岁老年女性，面部有严重的丘疹-结节性红斑病变，且持续存在。

查体：双侧颈部、腋窝和腹股沟淋巴结肿大。

影像学：弥散性淋巴结肿大和肝脾肿大。

皮肤和淋巴结活检： 低分化滤泡性淋巴瘤浸润皮肤。

这种罕见的疾病通常会被误诊为肉芽肿性酒渣鼻、面部播散性粟疹样狼疮、持续性节肢动物叮咬反应、或其他炎症性皮肤病。

该疾病通常可以通过组织活检得出精确诊断。原发的皮肤滤泡性淋巴瘤更常见，不过如果患者出现了全身症状，则该诊断可能性小。

原始出处：

Samer Tabchi,Tarek Assi,et al.Follicular lymphoma infiltrating the skin.BMJ 2015;351:h5449


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826076, encodeId=7caf18260e6bb, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Mar 15 00:23:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847744, encodeId=e7b7184e744fe, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Sep 14 09:23:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278762, encodeId=fb5a12e8762be, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467105, encodeId=e6ca146e105c1, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=)]
    2016-03-15 一叶知秋

    #皮肤病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1826076, encodeId=7caf18260e6bb, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Mar 15 00:23:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847744, encodeId=e7b7184e744fe, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Sep 14 09:23:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278762, encodeId=fb5a12e8762be, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467105, encodeId=e6ca146e105c1, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=)]
    2016-09-14 gaoxiaoe

    #BMJ#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826076, encodeId=7caf18260e6bb, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Mar 15 00:23:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847744, encodeId=e7b7184e744fe, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Sep 14 09:23:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278762, encodeId=fb5a12e8762be, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467105, encodeId=e6ca146e105c1, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=)]
    2015-11-09 gongliu

    #滤泡性淋巴瘤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826076, encodeId=7caf18260e6bb, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Mar 15 00:23:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847744, encodeId=e7b7184e744fe, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Sep 14 09:23:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278762, encodeId=fb5a12e8762be, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467105, encodeId=e6ca146e105c1, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 06:23:00 CST 2015, time=2015-11-09, status=1, ipAttribution=)]
    2015-11-09 syscxl

    #罕见#

    0

相关资讯

J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加

来那度胺和利妥昔单抗 (LR) 对滤泡性淋巴瘤(FL)治疗均有效。研究者进行了一项研究比较对于复发性FL患者，使用来那度胺+利妥昔单抗 vs 来那度胺，两种治疗方案各自优劣。CALGB 50401 (Alliance)是2期随机试验，包括以下分组：一组利妥昔单抗（每周 375 mg/m(2)，持续4周）；一组来那度胺（15mg/d，从第1天到21天，然后停药7天；第二个周期剂量加到20mg，一共进

JCO：血清中高维生素D水平可能改善滤泡性淋巴瘤的预后

目的：最近有文献报导高维生素D和淋巴瘤预后的改善之间存在潜在联系。我们评估了预处理维生素D对滤泡性淋巴瘤（ FL ）预后的影响。 方法：SWOG参与者是之前未经治疗而纳入SWOG临床试验（ S9800 ， S9911 或S0016）的FL患者，让他们在1998~2008年接受CHOP化疗方案辅以抗CD20抗体（利妥昔单抗或碘131托西莫单抗）治疗。我们第二独立组的参与者也是那些之前未经治疗被招收